FDA EUA approval is 100% linked to meeting the 'Primary Endpoints'. Absolutely NOTHING else matters.... no matter how good it is!!! Gotta meet the 'Primary Endpoints', or the FDA will reject it. This is exactly what happened to other promising small biotechs during the pandemic.
So the entire success or failure hinges on how well thought out the design of the "endpoints" are. Secondary endpoints do not matter.
News 
Market Data 
Discover 
